Fosmidomycin represents a new antimalarial drug, acting by inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, an essential enzyme of the mevalonate independent pathway of isoprenoid biosynthesis. This work describes the synthesis of a series of α-aryl substituted fosmidomycin analogues exhibiting improved antimalarial activity. A linear synthetic route, involving a 3-aryl-3-phosphoryl propanal intermediate, proved practical to prepare these derivatives. A phospha-Michael addition to cyclopent-2-enone gave access to conformationally restricted analogues.
Introduction
In the 1970s Kuemmerle and co-workers reported the first isolation of fosmidomycin as a structurally simple antibiotic from Streptomyces lavendulae. In recent years, fosmidomycin received considerable attention due to its promising antimalarial activity and recent clinical trials conducted in Gabon and Thailand confirmed the potential of fosmidomycin as antimalarial drug. 1 Chemical variations of fosmidomycin were mainly directed to increase the inhibitory activity against DXR or to achieve inhibitors with improved physicochemical properties. To study the structure-activity relationships, hydroxamic moiety modifications, including benzoxazolone and oxazolopyridinone functionalities, have been reported. 7 Also, the phosphonate moiety has been altered to produce prodrugs with improved oral bioavailability. 8, 9, 10 ,2 In 1998 the molecular target of fosmidomycin was discovered to be 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase. 3 This enzyme plays an essential role in the mevalonate-independent pathway for the synthesis of isoprenoids and is absent in humans. 4 Fosmidomycin was found to be a potent inhibitor for DOXP reductoisomerase (DXR) of P. falciparum. 5, 6 After this important discovery much attention has been focused on the chemical synthesis of fosmidomycin analogues. FR900098, the acetyl analogue of fosmidomycin, was shown to be approximately twice as active against P. falciparum in vitro as well as in a P. vinckei mouse model. 3 Surprisingly, modifications addressing the three carbon spacer are scarce. Recently, we reported the discovery of a series of α-aryl substituted fosmidomycin or FR900098 derivatives 1 and 2, which generally proved superior to fosmidomycin in inhibiting P.
falciparum growth. 11 To sort out the influence of the lipophilicity and electronic properties of this phenyl moiety, substituents were introduced according to Topliss' methodology.
-4 -Briefly, in this methodology an operational scheme is used to quickly identify the optimum substitution on a benzene ring for maximizing drug potency by virtue of resulting changes in hydrophobic, electronic and steric effects.
Here, we describe the detailed procedure used to synthesize these α-substituted analogues.
Although strategies to synthesise products with a C-P bond are well documented, 13 introducing aryl substituents in α-position of a phosphonate (resulting in a P-CH(Ar)-C motive) is quite challenging. Fosmidomycin was first synthesised in the early eighties by Hemmi et al. using a Michaelis-Becker reaction. 14 This approach cannot be easily adapted to allow the synthesis of α-substituted derivatives.
In this study 3-aryl substituted 3-phosphoryl propanals were anticipated to be appropriate intermediates for the synthesis of a small series of α-aryl substituted fosmidomycin analogues.
Depending on the availability of the starting material, a lithiation-allylation-alkene oxidation sequence or a Michael addition will be considered for the synthesis of these intermediates (Scheme 1). A drawback of this strategy is that every derivative has to be synthesized de novo, which does not permit to prepare an extended series of the envisaged analogues.
However, when the proposed routes allow to obtain the desired analogues in good overall yields, they might be valuable for scale-up purposes, e.g., to prepare a selected inhibitor for in vivo studies. Interestingly, when applied to cyclopent-2-enone the Michael addition should be a useful approach to design unprecedented fosmidomycin analogues 3 and 4, in which the 3C spacer is part of a cyclopentane ring. Indeed, by incorporating the α-and β-carbon in a cyclopropane ring, we recently demonstrated that rigidification of fosmidomycin might result in potent DXR inhibitors. Retrosynthetic analysis toward the synthesis of the desired α-substituted fosmidomycin analogues is depicted in Scheme 1.
[Scheme 1]
Two synthetic pathways toward the aldehyde synthons were followed (Scheme 2). The first one started from the appropriate diethyl benzylphosphonate, which upon treatment with nBuLi in the presence of allyl bromide, afforded 6a,b in 97 and 33 % yield. 16 Oxidation of 6a,b
to the vicinal cis-diol with osmium tetraoxide in the presence of 4-methylmorpholine N-oxide followed by sodium periodate cleavage gave aldehydes 9a,b, which could be used in the next step without further purification.
[Scheme 2]
When the desired benzylphosphonate was not commercially available, an alternative strategy to prepare the desired aldehydes was followed. A 1,4-addition of triethyl phosphite to the appropriately substituted cinnamaldehyde in the presence of phenol gave the acetals 8c-e in 70-85 % yield. 17 Subsequent deprotection of the diphenyl acetal afforded in 76-83 % yield the corresponding aldehydes, which appeared stable enough to be purified by flash chromatography. If necessary, substituted cinnamaldehydes were synthesized. Several procedures are described in the literature. In our hands a palladium-catalyzed synthesis from acrolein diethyl acetal and the corresponding aryl iodide was very efficient. 18 Only the (E)-isomer was obtained as deduced from the large coupling (16 Hz) between the vinylic hydrogens.
[ Scheme 3] Conversion of the appropriate aldehydes to the desired analogues 1 and 2 is depicted in Scheme 3. Treatment of 9a-e with O-benzylhydroxylamine yielded (67-92 %) oximes 10a-e. 
Synthesis of conformationally restricted fosmidomycin and FR900098 analogues
The approach used to convert the cinnamaldehydes 7c-e to the corresponding α-substituted fosmidomycin derivatives, was also successfully applied to prepare four 5-membered cyclic fosmidomycin analogues from cyclopent-2-enone (Scheme 4). Michael addition of triethyl phosphite to this cyclic α,β-unsaturated ketone gave direct access to the diethyl 3-oxocyclopentylphosphonate. 17 The remaining part of the synthesis involved the same transformations as used for the α-aryl phosphonates. Separation of the diastereomeric pairs was realized after the hydrogenolysis. The cis-and trans-isomers were assigned by 1 H
NOEDIF NMR experiments: an interaction between the NOH and the methyls of the phosphonate ester was observed for cis-22 and cis-23, as opposed to the trans isomer where such a contact was missing. The 13 C NMR spectra of compounds 22 further point to the presence of a major and a minor form, most probably as a result of restricted rotation in the hydroxamic group with preferential formation of the syn isomer due to a likely hydrogen bond between NOH and the carbonyl.
By using the described procedures, we have synthesized eleven analogues, allowing to perform initial SAR studies for the α-aryl series. 11 Although these studies revealed that the α-aryl analogues were generally weaker E. coli DXR inhibitors than fosmidomycin, these analogues unambiguously surpassed the activity of fosmidomycin to inhibit P. falciparum growth. Remarkably, the formyl analogues 1c and 1e consistently outperformed the acetyl derivatives 2c and 2e, both in the enzyme and the parasite growth inhibition assay.
With an IC 50 value of 0.036 μM compound 1e emerged as the most promising analogue.
Amongst the fosmidomycin analogues in which the C-C-C spacer is part of a cyclopentane ring, the trans analogues proved notably more active than the cis isomers (Table 1) . This is in agreement with recent results obtained with cyclopropane fosmidomycin analogues, where a trans orientation of the phosphonate group and the hydroxyamide moiety also yielded the most potent inhibitor. 15 Remarkably, in the cyclopropane series, the inhibitory activity of the formyl analogues surpassed that of the acetyl derivatives, while an opposite trend was observed in the cyclopropane series.
Conclusion
In conclusion, a synthetic procedure for the preparation of α-aryl substituted fosmidomycin analogues was developed starting from (a ring substituted) benzylphosphonate. Alternatively, these analogues were also accessible via a Michael addition of triethyl phosphite to an appropriate cinnamaldehyde. The latter method was also successfully used to prepare a series of cyclopentyl analogues of fosmidomycin.
Experimental
General IUPAC names were generated with Chemdraw Ultra 8. General method for synthesis of 9a,b
To a mixture of alkene 6a or 6b (6.56 mmol) and 4-methylmorpholine N-oxide (0.92 g, 7.87 mmol) in dioxane (40 mL) was added an aqueous 1 % solution of OsO 4 (99.1 mg, 0.39 mmol). After stirring overnight at room temperature and protected from light, the starting material was completely converted according to TLC. Then sodium periodate (2.24 g, 10.5 mmol) was added in small portions. After completion of the reaction (2 h), the mixture was diluted with ethyl acetate (100 mL), filtered through celite, and solids were washed with ethyl acetate. The combined filtrates were washed with saturated aqueous NaCl (100 mL), dried over MgSO 4 , and evaporated under vacuum to yield crude 9a or 9b, which were used in the next step whitout further purification.
General method for synthesis of 9c-e
Acetals 8c-e (5.0 mmol) were hydrolyzed by treatment with a mixture of water (7 mL Two methods have been used for the formylation of compounds 11 and 19.
Method A involves the use of 2-thioxothiazolidine-3-carbaldehyde, which was obtained as follows. Formic acid (1 eq.) and 2-mercaptothiazoline (1 eq.) were dissolved in CH 2 Cl 2 (0.5 M), cooled to 0 °C and DCC (1 eq.) was added in one portion. After the reaction mixture was filtered and evaporated, the residue was chromatographed (CH 2 Cl 2 ) to afford 2-thioxothiazolidine-3-carbaldehyde as a yellow solid.
Diethyl 3-(N-(benzyloxy)formamido)-1-(phenyl)propylphosphonate (12a).
2-Thioxothiazolidine-3-carbaldehyde (1 eq.) was dissolved in CH 2 Cl 2 and added to a solution of 11a (1 eq.) in CH 2 Cl 2 (0.1 M). The reaction mixture was stirred for 3 days. The reaction mixture was extracted with water, dried over MgSO 4 and evaporated in vacuo. The residue was purified by flash chromatography (CH 2 Cl 2 /MeOH 95:5) to yield 12a in a 89% yield. (2); 250 x 4.6 mm) using the same gradient at a flow rate of 1 mL/min. All final compounds were obtained as hygroscopic powders after lyophilisation. All powders were white, except the 5-membered cyclic analogues which were obtained as orange powders. 
3-(N-hydroxyformamido)-1-(3,4-dichlorophenyl)propylphosphonic acid (1e

